- Home
- CRTO vs NVAX Comparison
CRTO vs NVAX Comparison
Compare CRTO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- NVAX
- Stock Information
- Founded
- CRTO 2005
- NVAX 1987
- Country
- CRTO France
- NVAX United States
- Employees
- CRTO N/A
- NVAX N/A
- Industry
- CRTO Advertising
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRTO Consumer Discretionary
- NVAX Health Care
- Exchange
- CRTO Nasdaq
- NVAX Nasdaq
- Market Cap
- CRTO 2.3B
- NVAX 2.0B
- IPO Year
- CRTO 2013
- NVAX 1995
- Fundamental
- Price
- CRTO $34.21
- NVAX $9.76
- Analyst Decision
- CRTO Buy
- NVAX Buy
- Analyst Count
- CRTO 10
- NVAX 6
- Target Price
- CRTO $53.78
- NVAX $17.83
- AVG Volume (30 Days)
- CRTO 251.2K
- NVAX 7.2M
- Earning Date
- CRTO 10-30-2024
- NVAX 11-07-2024
- Dividend Yield
- CRTO N/A
- NVAX N/A
- EPS Growth
- CRTO 1230.66
- NVAX N/A
- EPS
- CRTO 1.65
- NVAX N/A
- Revenue
- CRTO $1,956,857,000.00
- NVAX $987,667,000.00
- Revenue This Year
- CRTO N/A
- NVAX N/A
- Revenue Next Year
- CRTO $6.88
- NVAX N/A
- P/E Ratio
- CRTO $24.81
- NVAX N/A
- Revenue Growth
- CRTO 1.64
- NVAX N/A
- 52 Week Low
- CRTO $22.10
- NVAX $3.53
- 52 Week High
- CRTO $49.93
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- CRTO 56.27
- NVAX 36.20
- Support Level
- CRTO $40.63
- NVAX $9.52
- Resistance Level
- CRTO $43.76
- NVAX $10.63
- Average True Range (ATR)
- CRTO 1.12
- NVAX 0.57
- MACD
- CRTO 0.23
- NVAX -0.12
- Stochastic Oscillator
- CRTO 74.54
- NVAX 9.97
About CRTO Criteo S.A.
Headquartered in Paris, Criteo is one of the leading ad-tech companies in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.